BG
NBIX icon

BlackRock Group’s Neurocrine Biosciences NBIX Stock Holding History

BlackRock Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$5.56M Sell
143,725
-154,804
-52% -$7.01M ﹤0.01% 1132
2016
Q3 		$15.1M Sell
298,529
-53,574
-15% -$2.67M 0.01% 839
2016
Q2 		$16M Buy
352,103
+40,132
+13% +$1.85M 0.01% 819
2016
Q1 		$12.3M Sell
311,971
-46,784
-13% -$1.86M 0.01% 874
2015
Q4 		$20.3M Buy
358,755
+140,356
+64% +$7.13M 0.01% 776
2015
Q3 		$8.69M Sell
218,399
-10,401
-5% -$503K 0.01% 956
2015
Q2 		$10.9M Buy
228,800
+25,044
+12% +$1.06M 0.01% 940
2015
Q1 		$8.09M Sell
203,756
-16,436
-7% -$588K ﹤0.01% 1013
2014
Q4 		$4.92M Sell
220,192
-21,386
-9% -$405K ﹤0.01% 1132
2014
Q3 		$3.79M Buy
241,578
+2,749
+1% +$41.1K ﹤0.01% 1182
2014
Q2 		$3.54M Sell
238,829
-10,107
-4% -$143K ﹤0.01% 1241
2014
Q1 		$4.01M Buy
248,936
+231,830
+1,355% +$3.97M ﹤0.01% 1204
2013
Q4 		$159K Sell
17,106
-18,776
-52% -$183K ﹤0.01% 2448
2013
Q3 		$406K Buy
35,882
+31,476
+714% +$433K ﹤0.01% 2305
2013
Q2 		$59K Buy
+4,406
New +$54.1K ﹤0.01% 2423

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Group's NBIX Position: Q4 2016 in Review

BlackRock Group reduced its Neurocrine Biosciences (NBIX) stake by 52% in Q4 2016, selling an estimated $7.01M and leaving 143,725 shares worth $5.56M. The position accounts for ﹤0.01% of the portfolio, ranked #1132.

BlackRock Group first reported a position in NBIX in Q2 2013 and has held it in 15 quarters since. The position peaked at $20.3M in Q4 2015. 225 funds tracked by Wall St. Rank hold NBIX as of Q4 2016.

  • BlackRock Group held 143,725 shares of Neurocrine Biosciences worth $5.56M as of Q4 2016.
  • BlackRock Group sold 154,804 Neurocrine Biosciences shares in Q4 2016, an estimated $7.01M.
  • Neurocrine Biosciences made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #1132 holding.
  • BlackRock Group first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Group's Neurocrine Biosciences position peaked at $20.3M in Q4 2015.
  • 225 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.